Cardiac drug developer Braveheart banks more than $382M in IPO
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.